searches have resulted in the discovery of 2 closely related antibacterial agents, cinodine and coumamidine4j5). Cinodine has been shown to be a specific inhibitor of bacterial gyrase. We have screened culture broths of bacteria, actinomycetes, and fungi to find additional chemical structures which selectively interact with bacterial gyrase. A known antibiotic, clerocidin6'7), was identified in this screen. Kawada et al.8) have recently shown that clerocidin induces eucaryotic topoisomerase II mediated double strand breaks. In this note we show that clerocidin inhibits DNAsupercoiling by bacterial gyrase and causes bacterial gyrase mediated DNAcleavage. That this interaction is the primary modeof action of clerocidin is indicated by the selectioa of a mutation in Escherichia coli causing resistance to clerocidin which is in the gyrA gene. A component in a fermentation broth ofFusidium viride was identified in a screen for agents which interact with E. coli gyrase by the same mechanism as nalidixic acid. This component was isolated and shown to be identical to clerocidin (Fig.  1 ).
Clerocidin had previously been identified as a cytotoxic agent5)6), and has recently been shown to stabilize the eucaryotic topoisomerase II cleavable complex8). The effect of clerocidin on supercoiling by bacterial gyrase was tested. Fig. 2 shows a series of supercoiling assays using relaxed pBR322 as a substrate for E. Coli gyrase. These data clearly show inhibition of the gyrase mediated supercoiling at the higher concentrations of clerocidin (lanes 8, 9, 10 and ll) and by control drugs (nalidixic acid, lane 4
and ciprofloxacin, lane 3). In these experiments supercoiling was inhibited 50% by approximately 10 /jm clerocidin.
Nalidixic acid and oxolinic acid are potent inhibitors of DNAgyrase and appear to stabilize the DNAcleavage complexes at specific sequences Plasmid pBR322 was incubated with E. coli gyrase, made from overproducing strains as described previously12), and drugs as described by Reece and MAXWEik.13 Cleavage reactions were performed on pOBS2A,a plasmid derived from the ICPO promoter region of herpes simplex virus type 1. The DNAis a BamHI to Ava I fragment of 120bp labeled at the BamRI site. Cleavages were carried out with approximately 20,000 CPM(5 ng) of DNAand 10 units of purified topoisomerase II (final volume of 20//I) in cleavage buffer (30mM Tris-HCl, pH 7.6, 60mMKC1, 8mM MgCl2, 15 mM2-mercaptoethanol, 3 mMATP, 30 /ig BSA/ml). Termination of reactions and analysis of cleavage products on DNAsequencing gels was performed as described by Chunget al.14). The cleavage substrate specified in the experiment was labelled at a single 5' end using polynucleotide kinase as described elsewhere15 1.5, 3.0, 15, 30, 150, 300, 600, 1,500 and 3,000. unique to each compound. Cleavage sites can be mapped by incubating the enzyme with a 5' end-labeled DNA, terminating the reaction with a protein denaturant (SDS) and sequencing the cleavage sites relative to chemical sequence markers9'10). This analysis reveals whether a particular agent sufficiently stabilizes the topoisomerase cleavage complex to allow its detection upon addition of SDS and also reveals sequence specific cleavages unique to the test compound. Fig. 3 shows specific cleavage fragments formed when eukaryotic topoisomerase II and gyrase are incubated with clerocidin, teniposide, and m-AMSA. The fragments formed when clerocidin is incubated with gyrase are seen in lanes 21~27 of Fig. 3 . Thus, clerocidin causes sequence-specific DNAcleavage when incubated with bacterial DNA gyrase in addition to inhibiting supercoiling.
Consistent with the results reported by Kawada et al.8\ cleavage bands are also observed when clerocidin is incubated in the presence of topoisomerase II (Fig. 3 lanes 8~13) .
In this particular assay at equivalent concentrations ofclerocidin there is a higher yield of cleavage fragments from the DNA gyrase containing reactions than from the topoisomerase II containing reactions (compare Fig.   3 lanes 21-27 with lanes 7-13). At the highest concentrations of clerocidin DNAcleavage by both topoisomerase II and DNAgyrase is inhibited (lanes 13-15, 28, 29) .
Cleavage fragments are distinct for each combination of agent and enzyme (compare Fig. 3 lanes 4 , 5, 9, 18, 19 and 24 (Table 1) . Teniposide strongly inhibited DNA synthesis after 1 hour (60%reduction in incorporation) or after 6 hours (90% reduction) of exposure.
In contrast, clerocidin was less inhibitory (30% inhibition at 1 hour and 6 hours) suggesting that this agent could be less cytotoxic to animal cells than teniposide.
A collection of bacterial species for which mutants resistant to nalidixic acid or ciprofloxacin were available was used to assess the level of cross resistance of clerocidin. The data in Table 2 show that in all cases except Staphylococcus aureus both the ciprofloxacin-resistant mutants and the nalidixic acid-resistant mutants are also resistant to clerocidin. Since these nalidixic acid-resistant mutants and ciprofloxacin-resistant mutants are in the structural gene for the gyrase Aprotein, the cross resistance indicates that the mode of action of clerocidin also involves DNAgyrase.
To confirm that the observed interaction of clerocidin with gyrase is its primary modeof action, a mutation (cleRl) causing resistance to clerocidin was selected in E. coli strain HB101. This was done by growth in L broth containing inhibiting levels of clerocidin. The MICfor clerocidin of the resistant mutant, E. coli strain SGB864, is 22-fold higher than that of HB101. As shown in Table 3 the strain sensitive to the inhibitor. When SGB864 (cleRl) was transformed with a plasmid (pKC16) containing gyrAll) it regained sensitivity to clerocidin (Table   4 ). Thus, the cleRl mutation is located within the gyrA gene.
Interest in clerocidin and the structurally related antibiotic, terpentecin, has focused mainly on their cytotoxic and antitumor actions. However, Table 5 shows that clerocidin has broad spectrum antibacterial activity.
Its activity against the Grampositive bacteria tested is equal to or greater than that of ciprofloxacin.
Clerocidin has very good activity against anaerobic bacteria. It is more active than ciprofloxacin against these organisms.
